(Q37150465)

18 August 2017

1 reference

title

An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma (English)

1 reference

cost-effectiveness analysis

18 August 2017

0 references

1 reference

S D Sullivan

1

1 reference

18 August 2017

F Turk

series ordinal

2

1 reference

18 August 2017

publication date

1 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

63

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

670-684

1 reference

The global burden of asthma: executive summary of the GINA Dissemination Committee report

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Psychological factors and asthma quality of life: a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Asthma in the United States: burden and current theories

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

The burden of asthma with specific reference to the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Features that distinguish those who die from asthma from community controls with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Clinical review: severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Factors associated with mortality after an asthma admission: a national United Kingdom database analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Relationship between quality of life and clinical status in asthma: a factor analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

The impact of exacerbations on the asthmatic patient's preference scores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Reduction in oral corticosteroid use with mometasone furoate dry powder inhaler improves health-related quality of life in patients with severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

The limitations of severe asthma: the results of a European survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Costs of asthma are correlated with severity: a 1-yr prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Costs of asthma according to the degree of severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Asthma severity and medical resource utilisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

A comprehensive study of the direct and indirect costs of adult asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Persistent asthma: disease control, resource utilisation and direct costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

An international observational prospective study to determine the cost of asthma exacerbations (COAX).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Information created to evade reality (ICER): things we should not look to for answers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Recent asthma exacerbations: a key predictor of future exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

A systematic review of risk factors associated with near-fatal and fatal asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

A multiple cause-of-death analysis of asthma mortality in the United States, 1990-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Mortality in patients hospitalized for asthma exacerbations in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Feasibility of a national fatal asthma registry: more evidence of IRB variation in evaluation of a standard protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Management for severe Crohn's disease: a lifetime cost-utility analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Long-term treatment of multiple sclerosis with interferon-beta may be cost effective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Markers of Risk of Asthma Death or Readmission in the 12 Months Following a Hospital Admission for Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2008.01723.X

10.1111/J.1398-9995.2008.01723.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference